NEW YORK ( TheStreet) -- Aside from merger and acquisition speculation, nothing gets investors more anxious on Wall Street than earnings season.
This is a time when judgment is passed on our investment decisions. So as we enter the second week of these "midterm exams," we are going to looks at four companies that are essentially heading in three separate directions.
There is also an excellent trade opportunity that might emerge in Bank of America (BAC - Get Report). And finally, we will look at why it might be time to lighten up on Johnson & Johnson (JNJ - Get Report). Although it remains a strong long-term play, I think the stock may have reached its high mark of the year.
Buy IBMWith Big Blue's stock trading at less than $200, Wall Street appears to be getting this story completely wrong. First, despite ongoing concerns regarding corporate IT spending, the company's focus on business analytics and cloud services give it a vital role in the enterprise sector. This is in addition to its strong growth areas and forward-looking initiatives like its "smarter planet." Secondly, the company deserves a considerable amount of credit for having successfully navigated through this new consumer-centric market. Only a short couple of years ago, IBM was teetering on the brink of irrelevance, while the market was being led by more nimble and agile players such as Apple (AAPL) and Google (GOOG). The company is due to report its second-quarter earnings results on Wednesday after market close and I expect its recent trend of earnings beats to continue. Investors would be wise to accumulate shares prior to the announcement. For the quarter, investor should expect EPS to arrive at $3.43 on revenue of $26.36 billion, topping last year's quarter of EPS of $3.09. It's hard to imagine that at one point the company languished under a stifling corporate culture, one created by the declining rule of the enterprise. However, today, IBM is once again a beacon of power and has led a type of resurgence that two quarters ago seemed unimaginable. Today, in addition to a strong product pipeline that is second to none, its aggressive expansion into emerging markets, as well as its recent acquisitions continues to make it one of the best long-term plays on the market. The stock is a buy.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts